Documented batches Public COA verification Research use only Quality standards
Primal Platform
← Back to all peptide profiles
Cyclic peptide Approval and post-marketing data Human data available

Peptide database · P-031

Plecanatide

Plecanatide; Trulance

Plecanatide is a uroguanylin analogue used in a U.S.-authorised medicine for defined gastrointestinal indications.

01

Molecular profile

Molecular profile

Molecule class
Cyclic peptide
Origin
Synthetic analogue
Primary target system
Guanylatcyclase-C
Development stage
Authorised active substance
Structure note

Disulfidreiches Uroguanylin-Analogon.

02

Mechanism and signalling

Mechanism and signalling

The peptide activates luminal guanylate cyclase C and modulates cGMP-dependent intestinal secretion and sensitivity.

03

Scientific classification

Scientific classification

This profile maps Plecanatid to the research areas gastrointestinal. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.

Gastrointestinal signalling

Peptide-based regulation of secretion, motility and the intestinal barrier.

04

Evidence base

Approval and post-marketing data

PreclinicalEarly human dataClinical dataPhase IIPhase IIIApproval and post-marketing data

Evidence includes approval trials for specific oral medicines. It cannot be transferred to other formulations or research products.

05

Regulatory status

Specifically approved in the U.S.

Specifically approved in the U.S.

The substance has a specific U.S. approval. This does not constitute general authorisation in Germany or the European Union, nor approval of unlicensed products.

06

Safety and use notice

No dosing or administration recommendation

The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.

07

Sources and registries

Sources and registries